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EDITORIAL
Why should an angiogenic factor modulate tubular structure in
diabetic nephropathy? Some answers, more questions
In the late 1980s, the first two angiogenic growth factors,
which were then thought to be highly specific for the
vasculature, were isolated on the basis of their ability to
mediate vascular leakage (vascular permeability factor)
and proliferation of endothelial cells [vascular endothelial
growth factor (VEGF)] [1]. It was found by nucleotide
sequencing that these proteins were identical. The most
widely studied member of the VEGF family, VEGF-A, is
a 34–46 kD homodimeric glycoprotein that exists in at
least five different splice isoforms [1]. In humans, VEGF165
is the most abundantly expressed and secreted isoform.
VEGF binds on target cells to at least two high-affinity
tyrosine kinase receptors, VEGFR-1 and VEGFR-2 [1].
In the normal kidney, VEGFRs are expressed on endo-
thelial, mesangial, and interstitial cells [2], while VEGF
itself is expressed in podocytes, distal tubules, and col-
lecting ducts [3]. An in vitro study demonstrated VEGF
production in cultured human proximal tubules [4].
VEGF is a critical factor in the pathogenesis of pro-
liferative diabetic retinopathy, but what is the rationale
to study the VEGF system in the kidney? Since VEGF
was originally characterized as a vascular permeability
factor, it has been consequently implicated in several
proteinuric diseases, including diabetic nephropathy.
Circulating VEGF is elevated in diabetes, and increased
renal VEGF mRNA and protein levels are found in early
diabetic nephropathy [2]. In contrast, decreased VEGF
content, probably due to podocyte loss, has been de-
scribed in advanced diabetic glomerulosclerosis. In cul-
tured mouse podocytes, high ambient glucose stimulates
VEGF protein expression and this effect is largely medi-
ated by the transforming growth factor- (TGF-) [5].
A functional role for VEGF in diabetic nephropathy
was first demonstrated by the observation that mono-
clonal anti-VEGF antibodies administered to streptozo-
tocin-diabetic rats decreased hyperfiltration, albumin-
uria, and glomerular hypertrophy [6]. Since VEGF165
phosphorylates and activates eNOS, resulting in a local
increase in nitric oxide (NO), prevention of NO forma-
tion could therefore explain how anti-VEGF antibody
prevents diabetic hyperfiltration. A recent long-term
study of anti-VEGF antibodies in db/db mice with type
2 diabetes showed significant attenuation of albuminuria,
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glomerular lesions, and kidney hypertrophy [7]. How-
ever, the role of VEGF in the etiology of proteinuria
is not as straightforward as it seems. The cellular and
molecular targets for the effects of VEGF on macromo-
lecular permeability are far from being elucidated. On
the other hand, neutralizing circulating VEGF in normal
mice can actually induce proteinuria, and this is associ-
ated with down-regulation of nephrin expression [8]. In
addition, exogenous VEGF165 significantly enhances cap-
illary repair and convincingly improves renal function in
rats with experimental glomerulonephritis [3]. These
data indicate that a certain amount of VEGF is necessary
to maintain normal glomerular structure and function. Dis-
turbances of this delicate balance by either under- or
overexpression of VEGF may modulate the function of
the filtration barrier.
Although such a complex role for an angiogenic factor
in the glomerular microcirculation may be appreciated
even by the skeptics, the study by Senthil et al [9] in this
issue of Kidney International on VEGF’s modulation of
tubular epithelial structure in diabetes comes somewhat
as a surprise. Accumulating evidence suggests that dis-
ruption of the tubulointerstitial architecture determines
the outcome of diabetic nephropathy [10]. In fact, proxi-
mal tubular cell growth is one of the earliest renal abnor-
malities detected in diabetes [10]. It has been proposed
that high glucose–induced tubular hypertrophy results
in increased proximal reabsorption, which is sufficient to
reduce the signal for tubuloglomerular feedback, thereby
causing the glomerular filtration rate to increase [11].
On the other hand, there is increasing evidence that this
initial tubular hypertrophy evolves into a maladaptative
process through various mechanisms, including genera-
tion of reactive oxygen species, secretion of proinflam-
matory cytokines, expression of potential autoantigens,
and probably transdifferentiation into collagen-secreting
fibroblasts [10]. The morphologic end points of this pro-
cess are tubular atrophy and interstitial fibrosis.
Senthil et al [9] now report an early increase in
VEGF165 mRNA and protein expression in renal cortices
of mice with type 1 and type 2 diabetes [9]. The increase
in VEGF expression coincides with the development of
kidney hypertrophy. However, the exact cell type re-
sponsible for VEGF up-regulation was not determined,
but it is reasonable to assume that the tubular compart-
ment significantly contributed to this increase. The au-
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thors then tested whether exogenous VEGF may acti-
vate signal transduction pathways in a cultured mouse
proximal tubular cell line (MCT cells). Western blotting
revealed the presence of VEGFR-2 but not VEGFR-1
in these cells. Exogenous VEGF resulted in tyrosine
phosphorylation of VEGFR-2. VEGF stimulated PI 3-
kinase and also activated its downstream target, Akt/
PKB. This treatment was associated with increased de
novo protein synthesis. Inhibition of VEGF-mediated PI
3-kinase and Akt activation abolished VEGF-mediated
protein synthesis. Finally, VEGF stimulated phosphory-
lation of eukaryotic initiation factor 4E binding protein
(4E-BP1) in an Akt-dependent manner, indicating that
early events in protein translation may explain the stimu-
lation in protein synthesis.
Like any novel observation, the present study provides
raw material for further investigations. It would be im-
portant to clarify the nonangiogenic or hypertrophic ef-
fects of VEGF on the kidney in vivo. Although Senthil
et al [9] have shown that VEGF stimulates de novo
protein synthesis in cultured proximal tubular cells, this
may not definitively prove that tubuloepithelial hyper-
trophy was actually induced by VEGF. An increase in
protein synthesis is observed during different phases of
the cell cycle and also occurs during cellular prolifera-
tion. Criteria to measure hypertrophy have been clearly
defined and involve also looking at cell cycle regulation
[10]. Since potential proliferative effects were not as-
sessed, it remains uncertain whether VEGF really in-
duces hypertrophy. Nevertheless, the observation that
anti-VEGF antibody can reduce the increase in kidney
weight in diabetic db/db mice [7] support some role for
VEGF in tubuloepithelial hypetrophy. Finally, the rela-
tionship of VEGF to other growth factors needs to be
clarified. It has been previously demonstrated in vivo
and in vitro that interference with TGF- activation com-
pletely abolishes tubular hypertrophy [10]. Since TGF-
induces VEGF synthesis at least in podocytes [5], it
would be interesting to study whether some of the estab-
lished effects of TGF- in diabetic nephropathy are actu-
ally mediated through VEGF.
In summary, the present study by Senthil et al opens
new avenues of research in the pathophysiology of tubu-
lar hypertrophy in diabetes and the emerging role of
VEGF in the structural and functional manifestations of
diabetic nephropathy.
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